XOMA (US) LLC (XOMA) Retakes Control Of BPI From Zephyr Sciences, Inc.; XOMA Remains Committed To Development Of BPI In Multiple Indications
10/19/2005 5:09:36 PM
BERKELEY, Calif.--(BUSINESS WIRE)--July 15, 2005--XOMA Ltd. (Nasdaq:XOMA) today announced its decision to terminate its exclusive worldwide license agreement with Zephyr Sciences, Inc. (Zephyr) for the research, development and commercialization of products related to bactericidal/permeability-increasing protein (BPI), including its NEUPREX(R) product.
"BPI's excellent safety profile continues to be an attractive feature in clinical use as evidenced by its ongoing evaluation in both pediatric and adult indications," said John L. Castello, chairman, president and chief executive officer of XOMA. "XOMA remains committed to the future development of BPI and is actively seeking new partnerships with private and public companies and in the public sector."